Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody
about
Recent advances in understanding hepatitis CEntry inhibitors: New advances in HCV treatmentHost-Targeting Agents to Prevent and Cure Hepatitis C Virus InfectionInterferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug ResistanceMouse Systems to Model Hepatitis C Virus Treatment and Associated ResistanceHepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.Antibody targeting of claudin-1 as a potential colorectal cancer therapy.Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro.One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1.Structural and functional hepatocyte polarity and liver disease.Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudinsNew perspectives for preventing hepatitis C virus liver graft infection.Hepatitis C Virus-Induced Upregulation of MicroRNA miR-146a-5p in Hepatocytes Promotes Viral Infection and Deregulates Metabolic Pathways Associated with Liver Disease Pathogenesis.Multifaceted role of E-cadherin in hepatitis C virus infection and pathogenesis.Hepatitis C virus depends on E-cadherin as an entry factor and regulates its expression in epithelial-to-mesenchymal transition.Humanized Mouse Models of Clinical Disease.Clinical development of hepatitis C virus host-targeting agents.Secreted Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro.Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.Attachment and Postattachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission.Hepatitis B virus receptors and molecular drug targets.A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies.Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases.Claudins in viral infection: from entry to spread.Claudin-targeted drug development using anti-claudin monoclonal antibodies to treat hepatitis and cancer.Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge.Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments.Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape."Hep C, where art thou": What are the remaining (fundable) questions in hepatitis C virus research?Dual blockade of hepatitis C virus entry at a gatekeeper of hepatocytes: Not only a preventive, but also therapeutic target of claudin 1.Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses.Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties.A plant-derived dehydrorotenoid: a new inhibitor of hepatitis C virus entry.When one receptor closes, another opens: claudins and the hepatitis C virus E1 glycoprotein.Engineered Livers for Infectious Diseases.Monoclonal antibodies against occludin completely prevented hepatitis C virus infection in a mouse model.
P2860
Q26766136-B065B0C4-AE08-47BB-825B-1B7FFC03E11FQ26770817-C049EE04-74CC-4A3C-9537-2A8D8FFC6378Q26779128-CF8A66C6-63F0-4222-AC7A-D827B8A0F7E9Q26781331-0AD440F8-A3B4-433E-8A12-0E8FC5C36EB9Q27469038-31C71D22-CBDD-4153-A9CF-5485FB41EAEAQ30386551-59AD46F3-D9F1-48A6-A746-BDFAAF055BC2Q33850900-9828B1DC-25F3-4A6B-8171-DD46AA29359AQ35828072-D916418C-0C6D-451A-A80D-C1D36C2F33C2Q35839680-DD7383A8-5207-46F5-8C04-43FB2FFAF591Q35863983-3B114F2D-95DF-426B-9376-7D301AF4DD87Q36090717-34145584-EC68-4826-86C2-5F5F1093DDC0Q36105419-667559BF-FF0B-411F-94DE-3CA6BEBF947DQ37015805-683AD819-D157-4854-ADC0-8B26AEA845FCQ37073281-0037A9CD-6AF5-4E01-A9DD-7A9DB15F7DB0Q37086640-66558360-4F01-4D8F-969D-CF3CC0014FE1Q37086661-C5576C7D-6C8B-4653-9D1A-1B259CB37F93Q37614202-9C3F8274-918B-4C35-8934-50FEA0697B68Q37662513-7BCD5EF5-AA23-4067-B662-06BF50593DC2Q37711751-CC32F7B4-6E4F-4782-95F2-9F786882C10EQ38602682-C23AA51B-E67D-4C74-ACDB-F911F7382F76Q38707908-2FBB49A0-6E9A-4466-8EF4-32C57E668172Q38775846-678D2FDE-88D2-4ED7-B157-6DB5B7A6CB41Q38809451-4B854B0D-710F-4132-9D0A-45C8E0EF4F16Q38856649-5AECDCD7-727D-4457-AE8E-66C4AFE3693AQ38997064-D303A3C1-838E-4206-BB54-F8D26CAB72D6Q39019295-A8C2F379-2E59-4D7A-AD8C-8BDD37078FD2Q39246243-780E43EE-ED29-4BEE-A917-D9B04A46769FQ39483891-51A6DA3C-8B10-41D1-BC07-F89F71E0DDC0Q40165519-1C4B0974-1575-465B-A6BF-EEA015E17CE5Q40198772-873FCF96-A318-42B6-84C2-AD7115E479E0Q40271516-10A453CE-BB67-4308-9034-D4B8655870B5Q40536482-9BD6371E-DAD0-48FF-A2E2-7FD39F6DE4BCQ40655024-4A077B9B-0240-4E03-8C39-C248FF678817Q41033867-02443A49-3CC2-414B-8B59-B9CC49432682Q41082130-6917F21A-2F09-4FE5-9CA4-EEE867AD9B0AQ41203252-D7104593-C0DC-479E-B874-DB13A8EA8784Q41981846-028C9392-4222-4427-8CD3-49FC5337CDB3Q42978515-31473230-5A8D-4E3D-BA9D-422C61B9B09FQ47555660-5E6B4802-102D-4C15-A275-4136FFE33D46Q50043321-86EFCDE3-5AD5-408C-846A-DD065868D603
P2860
Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Clearance of persistent hepati ...... -targeting monoclonal antibody
@ast
Clearance of persistent hepati ...... -targeting monoclonal antibody
@en
type
label
Clearance of persistent hepati ...... -targeting monoclonal antibody
@ast
Clearance of persistent hepati ...... -targeting monoclonal antibody
@en
prefLabel
Clearance of persistent hepati ...... -targeting monoclonal antibody
@ast
Clearance of persistent hepati ...... -targeting monoclonal antibody
@en
P2093
P2860
P50
P356
P1433
P1476
Clearance of persistent hepati ...... -targeting monoclonal antibody
@en
P2093
Béatrice Chane-Woon-Ming
Christine Thumann
Christopher Davis
Céline Leboeuf
Eric Robinet
François H T Duong
Garrick K Wilson
Helen J Harris
Isabel Fofana
Koen Vercauteren
P2860
P2888
P304
P356
10.1038/NBT.3179
P50
P577
2015-03-23T00:00:00Z